ClinConnect ClinConnect Logo
Search / Trial NCT03476577

Bariatric Surgery and Pharmacokinetics of Ibuprofen

Launched by NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY · Mar 19, 2018

Trial Information

Current as of July 21, 2025

Recruiting

Keywords

Bariatric Surgery Gastrointestinal Tract Biological Availability Pharmacokinetics Ibuprofen

ClinConnect Summary

This clinical trial is studying how bariatric surgery, specifically gastric bypass and sleeve gastrectomy, affects how the body processes ibuprofen, a common pain reliever. After these surgeries, changes in the stomach and intestines may alter how quickly or effectively medications like ibuprofen work. The goal of this research is to understand these changes better, as it could impact pain management for patients who have undergone such procedures.

To participate in this trial, you need to be preparing for gastric bypass or sleeve gastrectomy and be a citizen of Norway. Unfortunately, if you have had previous surgeries on your digestive system, you won't be eligible. If you join the study, you can expect to provide information about how ibuprofen works for you after your surgery, helping researchers learn more about medication use in patients who have undergone these weight-loss surgeries. Your participation could contribute valuable insights into improving care for others in similar situations.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Preparing to undergo gastric bypass or sleeve gastrectomy in Central Norway
  • Being a Norwegian citizen
  • Exclusion Criteria:
  • Having previously undergone resections in the GI-tract

About Norwegian University Of Science And Technology

The Norwegian University of Science and Technology (NTNU) is a leading research institution dedicated to advancing knowledge and innovation in various scientific fields. Renowned for its commitment to interdisciplinary collaboration, NTNU plays a pivotal role in addressing global health challenges through rigorous clinical trials and research initiatives. The university's emphasis on cutting-edge technology and its strong partnerships with healthcare sectors position it as a key player in translational research, ensuring that findings contribute effectively to improving public health and patient care. With a focus on ethical standards and scientific integrity, NTNU is dedicated to fostering advancements that enhance the quality of life and health outcomes for diverse populations.

Locations

Trondheim, , Norway

Patients applied

0 patients applied

Trial Officials

Magnus Strømmen, MSc

Principal Investigator

St. Olavs University Hospital

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials